


## Appendix C: Vaccinator Infographic

**Primary Series:** Most individuals need two doses of a COVID-19 Vaccine (mRNA, Novavax<sup>1</sup>) to complete a primary series. Those aged six months to four years will require two to three doses, depending on vaccine product. Immunocompromised individuals are recommended to receive an additional dose to complete their primary series.


**Booster Doses:** All Individuals five years of age and older are eligible to receive a booster dose once their primary series is complete. The interval for receiving a booster is six months (168 days) after their last dose or confirmed COVID-19 infection.<sup>2</sup>

### Children Aged 6 months – 4 Years<sup>3</sup>

Preferential Recommendation<sup>4</sup>




**SPIKEVAX/MODERNA**  
Age: 6 months–5 years  
Dilute: NO  
Dose: 25mcg/0.25ml




2 doses

 or 




3 doses

Immunocompromised




**COMIRNATY/PFIZER**  
Age: 6 months–4 years  
Dilute: With 2.2ml  
Dose: 3mcg/0.2ml




3 doses

 or 



4 doses

Immunocompromised



**Primary Series Intervals Between Doses**  
**Moderna:** Recommended: 56 days Minimum: 28 days  
**Pfizer:** Minimum: 21 days between dose 1 and 2  
Recommended: 56 days between remaining doses

**Mixing Doses**


Those aged 6 months to 4 years are recommended to be administered the same vaccine product for all doses in a primary series, using the correct dose for their age at the time of administration.<sup>5</sup>

**Booster Doses**


Booster doses have not been approved for children aged 6 months–4 years at this time

### Children Aged 5-11 Years

Preferential Recommendation<sup>4</sup>




**COMIRNATY/PFIZER**  
Age: 5-11 years  
Dilute: With 1.3ml  
Dose: 10mcg/0.2ml




2 doses

 or 




3 doses

Immunocompromised




**SPIKEVAX/MODERNA**  
Age: 6-11 years  
Dilute: NO  
Dose: 50 mcg/0.5ml  
50mcg/0.25ml




2 doses

 or 



3 doses

Immunocompromised



**Primary Series Intervals Between Doses**  
Recommended: 56 days Minimum: 28 days


**Mixing Doses**

Children who did not complete their primary series before turning five and received Pfizer (3mcg) are recommended to complete a 3-dose series using the correct dose for their age at the time of administration (i.e., Pfizer 10mcg).<sup>5</sup>


**Booster Doses**

### Individuals Aged 12 Years and Older

Preferential Recommendation<sup>4</sup>




**COMIRNATY/PFIZER**  
Age: 12+ years  
Dilute: NO  
Dose: 30mcg/0.3ml




2 doses

 or 




3 doses

Immunocompromised




**SPIKEVAX/MODERNA**  
Age: 12+ years  
Dilute: NO  
Dose: 100mcg/0.5ml




2 doses

 or 



3 doses

Immunocompromised



**Primary Series Intervals Between Doses**  
Recommended: 56 days Minimum: 28 days

**Mixing Doses**

Individuals aged 12 years and older may be administered vaccine products interchangeably, using the correct dose for their age.<sup>5</sup>

**Booster Doses**

Booster Doses Recommendations

Individuals 5 years and older who have not received a booster dose since September 1, 2022, remain recommended to receive a booster dose if it has been at least six months (168 days) since their last dose or confirmed COVID-19 infection.<sup>2</sup> If a booster dose has been received on or after September 1, 2022 (either monovalent or bivalent), there is no current evidence that substantiates the need for an additional dose, beyond the high-risk groups listed below.

Ontario’s Spring 2023 Booster Recommendations:

Individuals in specific high-risk populations are recommended to receive a spring booster dose if at least six months (168 days) have passed since their last dose or confirmed COVID-19 infection.<sup>2</sup>



High-Risk Groups:

- Individuals aged 65 years and older
- Residents of long-term care homes, retirement homes, elder care lodges, and other congregate living settings for seniors
- Individuals 18 years and older living in congregate care setting for people with complex medical needs
- Pregnant individuals
- Individuals aged 18 years and older who are moderately to severely immunocompromised
- Individuals aged 55 years and older who identify as First Nations, Inuit or Métis and their non-Indigenous household members aged 55 years and older.

Boosters for Children Aged 5-11 Years

 <b>COMIRNATY/PFIZER Bivalent</b> Age: 5-11 years Dilute: With 1.3ml Dose: 10mcg/0.2ml <small>Preferential Recommendation<sup>4</sup></small>	 <b>SPIKEVAX/MODERNA Bivalent BA.1</b> Age: 6-11 years Dilute: NO Dose: 25mcg/0.25ml
--	--

Boosters for Individuals Aged 12-17 Years

 <b>COMIRNATY/PFIZER Bivalent</b> Age: 12+ years Dilute: NO Dose: 30mcg/0.3ml <small>Preferential Recommendation<sup>4</sup></small>	 <b>SPIKEVAX/MODERNA Bivalent BA.1</b> Age: 12-17 years Dilute: NO Dose: 50mcg/0.5ml
---	--

Boosters for Individuals Aged 18 Years and Older

 <b>COMIRNATY/PFIZER Bivalent</b> Age: 12+ years Dilute: NO Dose: 30mcg/0.3ml	 <b>SPIKEVAX/MODERNA BA.1 or BA.4/5</b> Age: 18+ years Dilute: NO Dose: 50mcg/0.5ml
---	---

This document can be used as a reference for vaccine clinics and vaccine administrators to support COVID-19 immunization and is not intended take the place of medical advice, diagnosis or treatment, or legal advice. In the event of conflict between this document and any applicable emergency orders, or directives issued by the Minister of Health, Minister of Long-Term Care, or the Chief Medical Officer of Health, the order or directive prevails. Check the Ministry of Health COVID-19 website for updates to COVID-19 Vaccine Guidance.

<sup>1</sup> Novavax may be offered as a primary series to individuals who are aged 12 years and older and as a booster dose to individuals 18 years and older without contraindications to the vaccine who are not able or willing to receive an mRNA COVID-19 vaccine. Janssen may be offered to individuals who are aged 18 years and older without contraindications to the vaccine who are not able or willing to receive either an mRNA vaccine or a Novavax vaccine. Informed consent is required.

<sup>2</sup> A previous infection with SARS-CoV-2 is defined as: Confirmed by a molecular (e.g., PCR) or rapid antigen test; or Symptomatic AND a household contact of a confirmed COVID-19 case.

<sup>3</sup> For immunocompromised children aged six months to four years there is a preferential recommendation for monovalent Moderna (25 mcg) due to feasibility of series completion of the primary series rather than any safety signals observed. A 4-dose primary series with Pfizer-BioNTech (3 mcg) may have feasibility challenges.

<sup>4</sup> Pfizer is preferred for those 5-29 receiving a primary series and those <18 years receiving a booster dose.

<sup>5</sup> For guidance on managing COVID-19 vaccine administration errors and deviations, please see the Government of Canada’s [Planning guidance for immunization clinics for COVID-19 vaccines: Managing vaccine administration errors or deviations](#) and the Ontario Immunization Advisory Committee’s (OIAC) Recommendations: [Management of Age-Related COVID-19 Vaccine Administration Errors](#) . Where there is conflict between the two resources above, please refer to OIAC recommendations.